Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8843146 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1MAPTCYP2D6 | |
| SCHEMBL14286694 | 0.85 | NPC1 (0.42) | KMT2AMEN1KIF11 | |
| SCHEMBL890354 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL25598334 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL16472145 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL25969983 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL14847398 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL20149858 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL8843149 | 0.82 | KMT2A (0.40) | ALDH1A1KMT2AMEN1MAPTADRB2 | |
| SCHEMBL27081269 | 0.81 | MEN1 (0.38) | KMT2AMEN1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313984-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | Genscript USA Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204102-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | RNGTT, DTYMK, UNG | ALDH1A1 4471/4885KMT2A 1002/4885MEN1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.